MCK · Q1 2026 Earnings
BullishMcKesson Corporation
Reported August 6, 2025
30-second summary
McKesson delivered $97.8B in Q1 revenue (+23% YoY) and $8.26 adjusted EPS, driven by U.S. Pharmaceutical's 25% top-line growth and a 17% segment operating profit jump tied to GLP-1 volumes, oncology, and specialty. Management raised FY26 adjusted EPS guidance to $37.10–$37.90, but came clean in Q&A that the $0.20 raise is entirely Norway held-for-sale accounting — not an operational mark-up — and that PTS and Medical-Surgical guidance is unchanged despite a strong Q1. The aggressive posture is in capital deployment: $3.4B spent on Prism Vision and Core Ventures, $581M in buybacks, and a 15% dividend hike, all while reaffirming $2.5B of FY26 repurchases.
Headline numbers
EPS
Q1 FY2026
$8.26
Revenue
Q1 FY2026
$97.80B
+23.0% YoY
Gross margin
Q1 FY2026
3.4%
Free cash flow
Q1 FY2026
$-1.10B
Operating margin
Q1 FY2026
1.1%
Key financials
Q1 FY2026| Metric | Q1 FY2026 | YoY |
|---|---|---|
| Revenue | $97.80B | +23.0% |
| EPS | $8.26 | — |
| Gross margin | 3.4% | — |
| Operating margin | 1.1% | — |
| Free cash flow | $-1.10B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q1 FY2026| Segment | Q1 FY2026 | YoY |
|---|---|---|
| U.S. Pharmaceutical | $90B | +25.0% |
| Prescription Technology Solutions | $1.4B | +16.0% |
| Medical-Surgical Solutions | $2.7B | +2.0% |
| International | $3.7B | +1.0% |
| U.S. Pharmaceutical Adjusted Operating Profit | $950 million | — |
| Prescription Technology Solutions Adjusted Operating Profit | $269 million | — |
| Medical-Surgical Solutions Adjusted Operating Profit | $244 million | — |
| International Adjusted Operating Profit | $99 million | — |
Other KPIs
Q1 FY2026| Segment | Q1 FY2026 |
|---|---|
| Adjusted Operating Profit Margin (Non-GAAP) | 1.46% |
| Quarterly Dividend Increase | $0.82 per share (15% increase) |
| Share Repurchases (Q1 FY2026) | $581 million |
| Adjusted Earnings Growth | 1% vs prior year Q1 |
Management tone
McKesson's posture is more acquisition-aggressive and platform-oriented than typical conservative healthcare-services communications. Five distinct shifts in framing came through this quarter:
GLP-1 from windfall to baseline. Last cycle's GLP-1 conversation treated the volumes as volatile upside. This quarter management explicitly owns both the size and the variability: GLP-1 revenue was $12.1B in Q1 (+38% YoY) and the CFO noted "we anticipate continued growth of GLP-1 medication" while caveating that "this growth may vary from quarter to quarter." The metric is now embedded in the base case rather than treated as a transient tailwind.
Medical-Surgical from divest target to leverage story. With separation pending, the prior framing of this segment was passive — a portfolio item awaiting structural action. This quarter it carries a 22% segment operating profit lift and the CFO highlighted "more than 450 basis points of year-over-year improvement in our consolidated operating expense to gross profit ratio," anchored by specific automation proof points (90% automation at certain DCs, COBOT deployment). Management is now selling the segment's operating execution, not just its eventual separation value.
Oncology from bolt-on to flywheel. Post-Core Ventures close, the CEO explicitly used flywheel language: "It broadens our footprint, including distribution volume and demand for our GPO services. It enhances patient care access within the community. With providers practicing on the same electronic health record system, it enables us to generate valuable data and insights." That's a moat narrative — distribution, GPO, EHR-driven data — rather than the steady-state specialty bolt-on framing of prior cycles.
Prescription Tech from prior-auth processor to access platform. The CFO repositioned RxTS as "leading scale of digitally connected solutions...addressing market and patient challenges in access, affordability, and adherence," citing 985,000 providers and 50,000 pharmacies as a network asset. The implication is that RxTS earnings power is less tied to the GLP-1 prior-auth cycle than the consensus narrative assumes.
Capital allocation from defensive to aggressive. $3.4B deployed on Prism Vision and Core Ventures in a single quarter, $2B of debt issuance taken "with confidence," $2.5B FY26 buyback intact, dividend +15%. The CEO framed this as enterprise capital discipline; in practice it's the most acquisition-heavy posture McKesson has signaled in several years, and the guidance raise (even if mechanically Norway-driven) lands in that same quarter.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Eric Percher · Nefron Research
On RXTS segment: Should guidance be viewed as a ceiling with difficult upside until back half of year? What elements could drive performance to upper end of range?
Management highlighted consistency in operating performance driven by utilization, program success, and continued investments. Key drivers identified as utilization, drug maturity in programs, and new product launches. Emphasized long-term growth sustainability through access, adherence, and affordability solutions.
Lisa Gill · JP Morgan
Core pharma strong results: impact of Rite Aid store closings? Cadence guidance considering acquisitions and operating profit growth?
Management stated Rite Aid's second bankruptcy has immaterial impact on operations with no expected impact on fiscal 2026. Highlighted utilization strength, new customer onboarding (cycled through), specialty/oncology growth, provider additions, and acquisitions contributing 6-7% to operating profit growth.
Daniel Grossleit · Citi
Biosimilar adoption acceleration and benefits in Part B (retina with PRISM) and Part D channels? Impact of Stelara biosimilars and PBM insourcing by Caremark?
Management stated biosimilar launches (Humira, Stelara) in Part D slow revenue but have minimal bottom-line impact. Excited about ILEA and retina biosimilar launches (post-PRISM closure). Characterized biosimilars as steady long-term earnings contributor and building block, not material quarter-to-quarter gains.
Charles Reed · TD Cowan
RFPS strong performance but operating income growth guidance unchanged. Any changes in GLP-1 expectations? Impact of recent prior authorization initiatives by insurers?
Management credited strong performance to prior authorization programs success, particularly GLP-1s and non-GLP-1 programs. Revenue benefited from strong 3PL business (described as lumpy quarter-to-quarter). Stated 'no' material behavioral changes from payer prior authorization policy shifts, noting one payer preference shift between programs but overall prior auth volumes remain strong.
George Hill · Deutsche Bank
Guidance raise driven by Norway sale; with U.S. pharma at high end of range, will PTS or medical come in at low end? Other one-time items expected?
Management clarified the 20-cent raise is specifically from Norway sale and held-for-sale accounting, not operational changes. Stated no changes to medical or RXTS segment guidance despite strong Q1 performance. U.S. pharma guidance raise reflects operational strength continuing through end of Q1. One quarter in, confident in overall performance and guidance.
What to watch into next quarter
Whether PTS or Medical-Surgical guides get raised in Q2. Both segments ran ahead of their FY ranges in Q1 and management held the guides flat. A raise in Q2 would validate the operational story; another hold suggests management sees back-half offsets they're not yet disclosing.
U.S. Pharmaceutical operating profit cadence vs. the "high end of 12–16%" framing. Q1 delivered +17% — at the high end. Watch whether the FY language moves explicitly above the range, or whether Q1 was the peak.
GLP-1 revenue trajectory and quarter-to-quarter volatility. GLP-1 was $12.1B in Q1 (+38% YoY). Management has flagged variability; watch the QoQ direction and whether Stelara/Humira biosimilar dynamics start showing up in volume mix.
Prism Vision and Core Ventures contribution disclosure. Acquisitions are 6–7 points of FY26 op-profit growth per management. Watch whether organic vs. inorganic splits are disclosed cleanly in Q2 — if not, that's an analytical gap to flag.
Free cash flow build. Q1 was -$1.1B against a $4.4–4.8B FY guide. Track whether Q2 sees the typical seasonal swing back; a soft Q2 would put the FCF guide at risk and pressure the $2.5B buyback pace.
Medical-Surgical separation timing and any updated structural commentary. Tone shifted toward operating execution this quarter; watch for either a defined separation timeline or further deferral language.
Sources
- McKesson Q1 FY2026 Earnings Press Release (SEC Exhibit 99.1, period ended June 30, 2025): https://www.sec.gov/Archives/edgar/data/927653/000092765325000105/mck_exhibit991x6302025.htm
- McKesson Q1 FY2026 earnings call commentary (CFO and CEO prepared remarks and Q&A as referenced)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.